Carmen Roncal

Dr. Carmen Roncal

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2011 in Nature
Verified
Journal Article
Closed access
PDF file
YTYukiji Takeda
Yukiji Takeda
SCSandra Costa
Sandra Costa
EDEstelle Delamarre
Estelle Delamarre
CRCarmen Roncal
Carmen Roncal
RORodrigo Leite de Oliveira
Rodrigo Leite de Oliveira
Massimiliano MazzoneMassimiliano Mazzone
Massimiliano Mazzone

30 October 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CRCarmen Roncal
Carmen Roncal
EMEsther Martínez-Aguilar
Esther Martínez-Aguilar
JOJosune Orbe
Josune Orbe
SRSusana Ravassa
Susana Ravassa
AFAlejandro Fernandez-Montero
Alejandro Fernandez-Montero
JPJosé A Páramo
José A Páramo
Peripheral artery disease (PAD) is a major cause of acute and chronic illness, with extremely poor prognosis that remains underdiagnosed and undertreated. Trimethylamine-N-Oxide (TMAO), a gut derived metabolite, has been associated with atherosclerotic burden. We determined plasma levels of TMAO by mass spectrometry and evaluated their association with PAD severity and prognosis. 262 symptomatic PAD patients (mean age 70 years, 87% men) categorized in intermittent claudication (IC, n = 147) and critical limb ischemia (CLI, n = 115) were followed-up for a mean average of 4 years (min 1-max 102 months). TMAO levels were increased in CLI compared to IC (P < 0.001). Receiver operating characteristic (ROC) curves for severity (CLI) rendered a cutoff of 2.26 µmol/L for TMAO (62% sensitivity, 76% specificity). Patients with TMAO > 2.26 µmol/L exhibited higher risk of cardiovascular death (sub-hazard ratios ≥2, P < 0.05) that remained significant after adjustment for confounding factors. TMAO levels were associated to disease severity and CV-mortality in our cohort, suggesting an improvement of PAD prognosis with the measurement of TMAO. Overall, our results indicate that the intestinal bacterial function, together with the activity of key hepatic enzymes for TMA oxidation (FMO3) and renal function, should be considered when designing therapeutic strategies to control gut-derived metabolites in vascular patients.

1 February 2011 in Cancer Research
Verified
Journal Article
Open access
PDF file
APAsís Palazón
Asís Palazón
Alvaro TeijeiraAlvaro Teijeira
Alvaro Teijeira
IMIván Martínez-Forero
Iván Martínez-Forero
SHSandra Hervás-Stubbs
Sandra Hervás-Stubbs
CRCarmen Roncal
Carmen Roncal
IMIGNACIO MELERO
IGNACIO MELERO
Agonist monoclonal antibodies (mAb) to the immune costimulatory molecule CD137, also known as 4-1BB, are presently in clinical trials for cancer treatment on the basis of their costimulatory effects on primed T cells and perhaps other cells of the immune system. Here we provide evidence that CD137 is selectively expressed on the surface of tumor endothelial cells. Hypoxia upregulated CD137 on murine endothelial cells. Treatment of tumor-bearing immunocompromised Rag−/− mice with agonist CD137 mAb did not elicit any measurable antiangiogenic effects. In contrast, agonist mAb stimulated tumor endothelial cells, increasing cell surface expression of the adhesion molecules intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and E-selectin. When adoptively transferred into mice, activated T lymphocytes derived from CD137-deficient animals entered more avidly into tumor tissue after treatment with agonist mAb. This effect could be neutralized with anti–ICAM-1 and anti–VCAM-1 blocking antibodies. Thus, stimulation of CD137 not only enhanced T-cell activation but also augmented their trafficking into malignant tissue, through direct actions on the blood vessels that irrigate the tumor. Our findings identify an additional mechanism of action that can explain the immunotherapeutic effects of agonist CD137 antibodies. Cancer Res; 71(3); 801–11. ©2011 AACR.

1 November 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DTDaniela Tirziu
Daniela Tirziu
ECEmmanuel Chorianopoulos
Emmanuel Chorianopoulos
KMKaren L. Moodie
Karen L. Moodie
RPRobert T. Palac
Robert T. Palac
ZZZhen W. Zhuang
Zhen W. Zhuang
MSMichael Simons
Michael Simons
Although studies have suggested a role for angiogenesis in determining heart size during conditions demanding enhanced cardiac performance, the role of EC mass in determining the normal organ size is poorly understood. To explore the relationship between cardiac vasculature and normal heart size, we generated a transgenic mouse with a regulatable expression of the secreted angiogenic growth factor PR39 in cardiomyocytes. A significant change in adult mouse EC mass was apparent by 3 weeks following PR39 induction. Heart weight; cardiomyocyte size; vascular density normalization; upregulation of hypertrophy markers including atrial natriuretic factor, β-MHC, and GATA4; and activation of the Akt and MAP kinase pathways were observed at 6 weeks post-induction. Treatment of PR39-induced mice with the eNOS inhibitor l-NAME in the last 3 weeks of a 6-week stimulation period resulted in a significant suppression of heart growth and a reduction in hypertrophic marker expression. Injection of PR39 or another angiogenic growth factor, VEGF-B, into murine hearts during myocardial infarction led to induction of myocardial hypertrophy and restoration of myocardial function. Thus stimulation of vascular growth in normal adult mouse hearts leads to an increase in cardiac mass.

1 August 2012 in Cancer Cell
Verified
Journal Article
Closed access
RORodrigo Leite de Oliveira
Rodrigo Leite de Oliveira
SDSofie Deschoemaeker
Sofie Deschoemaeker
AHAnne-Theres Henze
Anne-Theres Henze
KDKoen Debackere
Koen Debackere
VFVeronica Finisguerra
Veronica Finisguerra
Massimiliano MazzoneMassimiliano Mazzone
Massimiliano Mazzone

1 March 2010 in Gastroenterology
Verified
Journal Article
Closed access
MSMartin Schneider
Martin Schneider
KGKatie Van Geyte
Katie Van Geyte
PFPeter Fraisl
Peter Fraisl
JKJudit Kiss
Judit Kiss
JAJulian Aragones
Julian Aragones
PCPeter Carmeliet
Peter Carmeliet